Creative Biolabs brings a full range of integrated assays combining with high throughput and high content technology, to offer our global clients a more informative perspective of fungicidal MOA focused on interference with nucleic acid synthesis.
Although fungal cell envelope has long been considered as the primary target for most antifungal therapies, alternative targets keep emerging during recent years in the effort to overcome fungal infection and drug resistance. One novel fungicidal agent, flucytosine, was first discovered in the 1970s, shedding light upon a fire-new therapeutic target interference with nucleic acid synthesis. Until now, there have evolved several classes of antifungal drugs of this kind, both in clinic and under development, including flucytosine (incorporating into RNA, and inhibiting DNA synthesis after converting into 5FU), yatakemycin (alkylation of DNA molecule), icofungipen (inhibiting intracellular isoleucyl-tRNA).
Given the complication of nucleic acid synthesis, which involves a great variety of factors and pathways, Creative Biolabs simplifies this process by generally sorting it into three major aspects: interference with DNA, RNA, and relevant factors (such as enzymes and transcription factors) respectively. Aided by our advanced technique system, scientists of Creative Biolabs conduct multiple delicate tests to facilitate the investigation of the antifungal mechanism of action from custom compounds.
Flow cytometry represents one classic method to estimate relative DNA content in response to substance exposure. Combined with microscope observation and DAPI staining, we can collect further phenotype information, e.g. cell cycle arrest.
Whole-Genome Tiling DNA Microarray
High density, whole-genome tiling DNA microarray is a well-established platform, capable of performing specific transcriptome-wide profiles induced by compound treatment. Notably, this technique is exceptionally powerful for revealing unbiased transcriptional activity, alternative splicing and identifying RNA-binding interactions. We apply precisely-designed primers and probes to ensure complete coverage of the entire genome, and the results will be delivered in detailed report form.
Real-Time Quantitative PCR
Incorporating with DNA microarray, quantitative real-time PCR allows accurate detection of a range of processing defects of intron-containing mRNA, as well as tRNA and rRNA precursors, providing comprehensive illustrations of RNA-related impacts.
High Throughput Topoisomerase Screening
DNA replication requires a series of essential enzymes called topoisomerases to initiate the process, which also acts as a crucial target for many antimicrobial chemicals. We conduct high throughput screening for determining whether the investigated compounds can inhibit the activity of multiple topoisomerases, including gyrase, topo IV, and human topos I and II. The assay is also adaptable to analyzing other relevant enzymes, i.e. restriction enzymes.
Alternatively, Creative Biolabs is able to perform various customized assays to address specific issues. We also provide additional evaluation service to verify cross-reactivity potency with mammalian models. Our state-of-art technologies and seasoned experts will undoubtedly accelerate your drug antifungal drug developing programs and ensure future success.
For more detailed information, please feel free to contact us or directly sent us an inquiry.
For Research Use Only.
